Why Does Whole-Gland Prostate Treatment Affect Sexual Function?

Key Takeaways

• Sexual function depends on nerve bundles that run directly alongside the prostate — any treatment affecting the gland has some potential to affect those nerves nearby.
• In published TULSA-PRO data, erectile function commonly dips in the months immediately following treatment before recovering — this is a documented pattern, not a rare complication.
• At four years post-treatment, published trial data reported 87% of previously potent men had erections sufficient for penetration, with no severe erectile dysfunction cases.
• Whole-gland treatment carries a different risk profile than focal treatment, since more tissue near the nerve bundles is treated.
• Recovery timelines vary by individual — some men see improvement continue for years, not just months.

What's Actually at Risk During Whole-Gland Treatment?

The prostate sits close to a pair of nerve bundles — the neurovascular bundles — that run along its outer edges and play a central role in erectile function. Any treatment that affects the prostate has some potential to affect these nerves nearby, simply because of proximity, not because of any particular technology's shortcomings.

Whole-gland treatment, as the name suggests, treats the entire prostate rather than a single identified area.

That means more of the tissue near those nerve bundles is exposed to treatment energy, compared to a focal approach that targets only a specific region. This isn't unique to any one treatment modality — it's a structural reality of treating an organ that sits directly next to the tissue responsible for sexual function.

Why Do Some Men Experience a Temporary Decline Before Recovery?

Treatment causes localized inflammation and tissue healing near the treated area, and nerves that have been near an ablation zone can take time to recover normal signaling — similar in concept to how a nerve can be temporarily affected by swelling or pressure elsewhere in the body.

A peer-reviewed study following TULSA patients found erectile function was significantly reduced at both the 3–6 month and 9–12 month marks after treatment, even in cases without major complications.

This temporary pattern is documented, not something to be alarmed by on its own — but it's worth understanding going in, rather than being surprised by it afterward.

What Does Longer-Term Recovery Actually Look Like?

In the TACT pivotal trial, erectile function outcomes continued to shift over several years, not just the first few months.

Erections sufficient for penetration were reported by 75% of previously potent men at one year, improving to 87% by four years — with no patients experiencing severe erectile dysfunction at that four-year mark. Continence followed a similarly durable pattern: 94% of patients were completely pad-free at four years.

Recovery isn't always a straight line, and it isn't always finished at the one-year mark. For some men, meaningful improvement continues well beyond the point most people assume "recovery" is over.

Does Focal Treatment Avoid This Risk Entirely?

Not entirely, but the risk profile is generally lower, since less tissue near the nerve bundles is treated.

Whether focal treatment is appropriate depends on whether your specific cancer is confined to an identifiable area — not every case is a candidate, regardless of preference.

Common Questions

How soon after treatment might erectile function change? Published data shows changes are most likely to be noticeable in the first several months after treatment, with the potential for continued improvement over one to four years.

Is a temporary decline in sexual function normal after TULSA-PRO? Published research indicates temporary changes are common in the months following treatment. This doesn't predict your ultimate outcome — recovery patterns vary by individual and by follow-up duration in the studies available.

Does whole-gland treatment mean I'll definitely lose function? No. Published four-year data show the substantial majority of previously potent men retained function sufficient for penetration, with no severe erectile dysfunction reported in that trial. Individual results vary.

Sources:

• TACT pivotal trial 12-month outcomes, Journal of Urology (peer-reviewed); 4-year follow-up presented at AUA Annual Meeting, 2023
• Independent peer-reviewed monocentric study on TULSA functional outcomes, PMC/NCBI, 2023
• Johns Hopkins Medicine, "TULSA Gives New Options for Intermediate-Risk Prostate Cancer," 2026